乌达帕替尼治疗特应性皮炎的罕见不良反应--一名少女闭经

IF 2 3区医学 Q2 MEDICINE, GENERAL & INTERNAL

Patient preference and adherence Pub Date : 2024-11-14 eCollection Date: 2024-01-01 DOI:10.2147/PPA.S484647

Yan Teng, Yi Tang, Yibin Fan, Xiaohua Tao, Yang Ding

{"title":"乌达帕替尼治疗特应性皮炎的罕见不良反应--一名少女闭经","authors":"Yan Teng, Yi Tang, Yibin Fan, Xiaohua Tao, Yang Ding","doi":"10.2147/PPA.S484647","DOIUrl":null,"url":null,"abstract":"Atopic dermatitis (AD) is a common chronic inflammatory cutaneous disease. Upadacitinib, a selective JAK-1 inhibitor, has been approved as a systemic medication for moderate-to-severe AD in patients aged ≥12 years. Although previous studies have examined the safety profile of upadacitinib, this is the first report to describe a potential association between amenorrhea and upadacitinib or other JAK inhibitors. Herein, we report a rare adverse event of amenorrhea in an adolescent female patient who was treated with upadacitinib for AD. This case report expands the range of adverse events potentially associated with upadacitinib therapy.","PeriodicalId":19972,"journal":{"name":"Patient preference and adherence","volume":"18 ","pages":"2307-2310"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573685/pdf/","citationCount":"0","resultStr":"{\"title\":\"Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis.\",\"authors\":\"Yan Teng, Yi Tang, Yibin Fan, Xiaohua Tao, Yang Ding\",\"doi\":\"10.2147/PPA.S484647\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Atopic dermatitis (AD) is a common chronic inflammatory cutaneous disease. Upadacitinib, a selective JAK-1 inhibitor, has been approved as a systemic medication for moderate-to-severe AD in patients aged ≥12 years. Although previous studies have examined the safety profile of upadacitinib, this is the first report to describe a potential association between amenorrhea and upadacitinib or other JAK inhibitors. Herein, we report a rare adverse event of amenorrhea in an adolescent female patient who was treated with upadacitinib for AD. This case report expands the range of adverse events potentially associated with upadacitinib therapy.\",\"PeriodicalId\":19972,\"journal\":{\"name\":\"Patient preference and adherence\",\"volume\":\"18 \",\"pages\":\"2307-2310\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573685/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Patient preference and adherence\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/PPA.S484647\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Patient preference and adherence","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PPA.S484647","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

特应性皮炎（AD）是一种常见的慢性皮肤炎症。乌达帕替尼是一种选择性JAK-1抑制剂，已被批准作为一种全身用药，用于治疗年龄≥12岁的中度至重度特应性皮炎患者。尽管之前的研究已对乌达替尼的安全性进行了检查，但这是第一份描述闭经与乌达替尼或其他JAK抑制剂之间潜在关联的报告。在此，我们报告了一例罕见的闭经不良事件，患者是一名接受达帕替尼治疗 AD 的青春期女性患者。本病例报告扩大了可能与达达替尼治疗相关的不良事件的范围。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis.

Atopic dermatitis (AD) is a common chronic inflammatory cutaneous disease. Upadacitinib, a selective JAK-1 inhibitor, has been approved as a systemic medication for moderate-to-severe AD in patients aged ≥12 years. Although previous studies have examined the safety profile of upadacitinib, this is the first report to describe a potential association between amenorrhea and upadacitinib or other JAK inhibitors. Herein, we report a rare adverse event of amenorrhea in an adolescent female patient who was treated with upadacitinib for AD. This case report expands the range of adverse events potentially associated with upadacitinib therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Patient preference and adherence MEDICINE, GENERAL & INTERNAL-

CiteScore

3.60

自引率

4.50%

发文量

354

审稿时长

6-12 weeks

期刊介绍： Patient Preference and Adherence is an international, peer reviewed, open access journal that focuses on the growing importance of patient preference and adherence throughout the therapeutic continuum. The journal is characterized by the rapid reporting of reviews, original research, modeling and clinical studies across all therapeutic areas. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal. As of 1st April 2019, Patient Preference and Adherence will no longer consider meta-analyses for publication.